Expertise in
10
conditions

Dr. Basil T. Darras

Pediatric Neurology
Department Of Neurology
300 Longwood Ave, 
Boston, MA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
10
conditions
Department Of Neurology
300 Longwood Ave, 
Boston, MA 

Overview

Basil Darras is a Pediatric Neurologist practicing medicine in Boston, Massachusetts.

Dr. Darras is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 1, and Gastrostomy.

He is actively involved in clinical research, co-authoring 198 peer reviewed articles and participating in 15 clinical trials. Dr. Darras is currently accepting new patients.

Specialties

Pediatric Neurology

Licenses

Neurology with Special Qualifications in Neurology in MA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Department of Neurology
300 Longwood Ave, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy
Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy
Enrollment Status: Recruiting
Publish Date: November 24, 2025
A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Enrollment Status: Recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Other
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: March 10, 2026
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: January 26, 2026
Intervention Type: Biological
Study Phase: Phase 1
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 3
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 2
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
View 8 Less Clinical Trials

198 Total Publications

Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.
Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.
Journal: The Lancet. Child & adolescent health
Published: January 28, 2026
Similar Doctors
Expertise in
38
conditions
Dr. Mustafa Sahin
Pediatric Neurology
Expertise in
38
conditions
Dr. Mustafa Sahin
Pediatric Neurology
Referral may be required

Department Of Neurology

300 Longwood Ave, 
Boston, MA 
 (0.1 miles away)
617-919-5323
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Mustafa Sahin is a Pediatric Neurologist practicing medicine in Boston, Massachusetts. Dr. Sahin is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Tuberous Sclerosis, Tuberous Sclerosis Complex, Cortical Dysplasia, and Spastic Paraplegia Type 7. Dr. Sahin is currently accepting new patients.

Expertise in
11
conditions
Dr. Tobias Loddenkemper
Pediatric Neurology
Expertise in
11
conditions
Dr. Tobias Loddenkemper
Pediatric Neurology
Referral may be required

Department Of Neurology

300 Longwood Ave, 
Boston, MA 
 (0.1 miles away)
617-919-5323
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tobias Loddenkemper is a Pediatric Neurologist practicing medicine in Boston, Massachusetts. Dr. Loddenkemper is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Status Epilepticus, Seizures, Epilepsy in Children, and Epilepsy. Dr. Loddenkemper is currently accepting new patients.

Expertise in
21
conditions
Dr. Elizabeth A. Thiele
Pediatric Neurology | Neurology
Expertise in
21
conditions
Dr. Elizabeth A. Thiele
Pediatric Neurology | Neurology
Referral may be required

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.6 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Thiele is a Pediatric Neurologist and a Neurologist practicing medicine in Boston, Massachusetts. Dr. Thiele is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Tuberous Sclerosis Complex, Tuberous Sclerosis, Cortical Dysplasia, and Myoclonic Epilepsy. Dr. Thiele is currently accepting new patients.

Frequently Asked Questions about Dr. Basil T. Darras

How do I make an appointment with Dr. Basil T. Darras?

You can book an appointment with Dr. Basil T. Darras by calling their office at 617-919-5323. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Basil T. Darras a top-rated expert for Spinal Muscular Atrophy (SMA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Basil T. Darras is classified as an Elite expert for Spinal Muscular Atrophy (SMA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Basil T. Darras specialize in?

While Dr. Basil T. Darras is a Pediatric Neurology, they have specific expertise in Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, and Spinal Muscular Atrophy Type 2. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Neurology.

Does Dr. Basil T. Darras participate in research or clinical trials?

Yes. Dr. Basil T. Darras has published 198 articles and abstracts on conditions like Spinal Muscular Atrophy (SMA). You can view a list of Dr. Basil T. Darras's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Basil T. Darras accept my insurance?

Dr. Basil T. Darras accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-919-5323 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Darras's expertise for a condition
ConditionClose
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile